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a b s t r a c t
Introduction: Guillain–Barré Syndrome (GBS) is an acute immune-mediated peripheral
neuropathy with a highly variable clinical course and outcome. The aim: to assess the
frequency of different electrophysiological subtypes and antiganglioside antibodies in
Egyptian children with GBS and their association with clinical severity, and response to
therapy. Patients and methods: A prospective study included 47 patients fulﬁlling inter-
national criteria for GBS. Plasma levels of antiganglioside antibodies were measured on
admission by (ELIZA). GM1, GM2, GD1a and GD1b subtypes were tested. Nerve conduction
studies were performed after 2 weeks of onset of neurologic symptoms. Management
was started immediately by intravenous immunoglobulins (IVIG). If IVIG failed to do any
clinical improvement, ﬁve sessions of plasmapheresis was performed. Results: In the
present study AMAN subtype constituted a major form of GBS, 49%. In the AMAN group
a signiﬁcant number of patients, 16 (73%) had antiganglioside antibody positive results,
(P = 0.006). GD1b was signiﬁcantly higher in the AMAN group than in the AIDP group.
Clinical presentation in antiganglioside positive patients was frequently associated with
antecedent diarrhea and showed severe motor weakness necessitating mechanical venti-
lation than did seronegative patients, P value (<0.0001, 0.025) respectively. Most antigan-
glioside positive patients, 20 (95.5%) failed to respond to IVIG and responded well to
plasmapheresis, P value (<0.0001) compared with patients in the seronegative group.
Conclusion: Antiganglioside antibodies positive patients constitute a major subtype
among Egyptian children with GBS. They may be more reliable than electrodiagnosis in
determining the clinical severity and predicting the ongoing response to therapy.
© 2013 Polish Pediatric Society. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
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Guillain–Barré Syndrome (GBS) is an acute immune-media-
ted peripheral neuropathy with a highly variable clinical
course and outcome [1].
It is currently classiﬁed into several subtypes by electrop-
hysiological and pathologic criteria. The two major subtypes
are acute inﬂammatory demyelinating polyneuropathy
(AIDP) and acute motor axonal neuropathy (AMAN). AIDP is
the classic form of GBS and is characterized by demyelina-
tion as the main pathological process [2].
AMAN is caused by a heterogeneous group of antibiotics
directed against the human gangliosides on the axolemma
of motor ﬁbers. Autopsy studies in AMAN patients' revealed
degeneration in motor axons with IgG and complement
deposits without demyelination, suggesting that the disor-
der primarily involves the axonal membrane [3, 4].
The association of anti-ganglioside antibodies with some
clinical features of GBS has been documented in several
previous studies. Wilson and Yuki found a strong correla-
tion between some types of anti-ganglioside antibodies
particularly anti-GM1 and the rapid progressive course of
the disease [5]. Furthermore, this high anti-GM1 tended to
be associated with a worse disability 6 months after the
onset of paralysis [6]. Kusunoki et al. found the presence of
antibodies that speciﬁcally recognizes a new conformational
epitope formed by ganglioside complex in the acute-phase
sera of some GBS patients, and they demonstrated that
these antibodies were associated with severe GBS requiring
mechanical ventilation [7].
The purpose of this study was to determine the fre-
quency of different electrophysiological subtypes of GBS
among Egyptian children and their association with anti-
ganglioside antibodies and to ﬁnd a correlation between the
presence of theses antibodies and some clinical presenta-
tions of GBS. In addition we also assessed the role of
antiganglioside antibodies in determining the response to
different therapeutic interventions.
Subjects and methods
Study design, population and setting
This prospective cohort study included 47 patients fulﬁlling
international criteria for GBS [8], with inability to walk 10 m
independently and within two weeks from the onset of
neuropathy. Patients were selected from Pediatric Intensive
Care Unit (PICU) of Cairo University Specialized hospital,
9 bed capacity, from the period of January 2010 to Septem-
ber 2012.
All patient were subjected to Full history and data
analysis including age, sex, antecedent illness, complete
clinical and neurological examination including; motor and
sensory systems, pattern of respiration and evidence of
respiratory failure on admission, mechanical ventilation
need and therapy with immunoglobulins or further need for
plasmapharesis were recorded.Assessment of motor function severity
Severity of GBS was scored on admission using (arm and
leg) motor disability grading functional scale [9]. Overall
disability sum score = arm disability scale (range 0–5) + leg
disability scale (range 0–7); overall range: 0 (no signs of
disability) to 12 (maximum disability).Clinical improvement
was noted by improvement in the motor functional grading
scale and successful weaning (decrease of mechanical
ventilator parameters) and extubation from mechanical
ventilation following therapy.
Treatment
Management was started immediately by intravenous
immunoglobulins (IVIG) in a standard dose of 400 mg/kg/day
for 5 successive days. If IVIG failed to do any clinical
improvement, ﬁve sessions of plasmapheresis for 5 succes-
sive days was performed using 5% albumin as replacement
ﬂuid and exchange volume 40–60 ml/kg per session.
Electrodiagnostic study
Nerve conduction studies were performed at the end of
the ﬁrst 2 weeks from the onset of neurologic symptoms.
Nerve conduction studies that showed unclassiﬁed results
were excluded from subsequent study analysis. Motor
conduction studies were performed on median, ulnar,
tibial and peroneal nerves in both sides, using conventio-
nal techniques. Sensory nerve conduction studies were
performed on median, ulnar and sural nerves using
conventional studies. Patients were classiﬁed as having
AMAN or AIDP on the basis of the electrodiagnostic
criteria proposed by Ho et al. [10].
Anti-ganglioside antibodies
Pretreatment serum sample was taken on admission and
frozen at 80 8C until sending for antiganglioside antibodies
assay.
The serum IgG antibodies against gangliosides GM1, GM2,
GD1a and GD1b subtypes were tested by ELISA on admis-
sion. This test is a qualitative enzyme-linked immunosor-
bent assay (ELIZA) for in vitro human antibodies assay in
serum. When at least one of the tested antibodies was
positive (>1:500), patients were regarded as antiganglioside
positive.
Statistical analysis
Patients were initially grouped by positivity of antiganglio-
side antibodies and then by the electrodiagnoses of AIDP
and AMAN. Summary statistics were constructed using
frequencies and proportions for categorical data, and
means and SDs for continuous variables. We compared
positive and negative groups as well as AMAN and AIDP
groups using the x2 test for categorical data, and t testes
for continuous variables. P value < 0.05 was considered
to be statistically signiﬁcant. All statistical analysis was
Table I – Total antiganglioside antibodies and final electrodiagnosis
Electrodiagnosis Antiganglioside antibodies Total (N = 47) P value
Positive (N = 22) Negative (N = 25)
AIDP 5 (23%) 15 (60%) 20 (43%) 0.02a
AMAN 16 (73%) 7 (28%) 23 (49%) 0.006a
Unclassiﬁed 1 (4%) 3 (12%) 4 (8%) NS
a Significant.
NS = non-significant.
Table II – Total and specific antiganglioside antibodies in
different subtypes of GBS
Antiganglioside
antibodies
AIDP
(N = 20)
AMAN
(N = 23)
P value
Total positive 5 (25%) 16 (70%) 0.009a
Speciﬁc positive:
Anti-GM1 2 (10%) 6 (26%) 0.337
Anti-GM2 3 (15%) 4 (17%) 0.839
Anti-GD1a 4 (20%) 6 (26%) 0.912
Anti-GD1b 1 (5%) 10 (43%) 0.011a
a Significant.
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Chicago, USA).
Results
A total of 47 patients with GBS were admitted to the PICU
within the ﬁrst two weeks from the onset of neuropathy
during the period of the study. There were 30 (64%) males
and 17 (36%) females. The mean age was 7.272  2.5 years.
Thirty-six (77%) children had antecedent illness; acute
respiratory infection in 13 patients (27.7%) and diarrhea in
23 patients (48.9%). Weakness (leg disability grade 5 or more
and arm disability grade 3 or more) was seen in 40 (85.1%)
patients, sensory symptoms in 19 (40.0%) patients, cranial
nerve palsy in 15 (31.9%) patients and autonomic dysfunc-
tion in 7 (14.9%) patients. Twenty-seven (57.4%) patients
needed mechanical ventilation. All patients received IVIG
and 31 patients (66%) underwent plasmapheresis. There was
no recorded mortality among patients studied.
Table I shows the relationship between antiganglioside
antibodies and electrodiagnosis ﬁndings. Patients with unc-
lassiﬁed electrodiagnosis ﬁndings were further excluded
from the rest of the study analysis. Fig. 1 shows distribution
of patients in the study according to electrodiagnosis
ﬁndings, and antiganglioside antibodies results. Table II
shows total and speciﬁc IgG antiganglioside antibodies
results in both subtypes of GBS. Table III shows the clinicalFig. 1 – Electrodiagnosis and antiganglioside antifeatures in the AMAN compared with AIDP groups. Table IV
shows the clinical features in the antiganglioside positive
compared with negative patients. Table V shows the clinical
features of GBS according to both the electrodiagnosis
ﬁndings and the antiganglioside antibody positivity.
Discussion
In the present study, AMAN subtype constituted a major
form of GBS in Egyptian children. Similar reports are found
all over the world. In Asia, it is reported that AMAN is
a major form of GBS, in Central and South America the
frequency is 35–65% [11–13].bodies distribution among patients with GBS
Table III – Clinical features of patients with GBS according
to electrodiagnosis
Electrodiagnosis
Variable AIDP
(N = 20)
N (%)
AMAN
(N = 23)
N (%)
P value
Sex (M/F) 13/7 15/8 0.759
Motor paralysis 17 (85) 21 (91) 0.520
Sensory impairment 14 (70) 4 (17) <0.0001a
Bulbar symptoms 7 (35) 6 (30) 0.526
Autonomic dysfunction 2 (10) 4 (17) 0.485
Antecedent ARI 5 (25) 6 (26) 0.935
Antecedent diarrhea 3 (15) 18 (78) <0.0001a
Mechanical ventilation 8 (40) 17 (74) 0.025a
Plasmapheresis 11 (55) 18 (78) 0.104
a Significant.
ARI: acute respiratory infection.
Table IV – Clinical features of patients with GBS according
to anti-ganglioside antibodies
Antiganglioside antibodies
Variable Positive
(N = 21)
N (%)
Negative
(N = 22)
N (%)
P value
Sex (M/F) 14/7 14/8 0.911
Motor paralysis 21 (100) 17 (77.3) 0.020a
Sensory impairment 2 (9.5) 16 (72.3) <0.0001a
Bulbar symptoms 6 (28.6) 7 (31.8) 0.817
Autonomic dysfunction 3 (14.3) 3 (13.6) 0.951
Antecedent (ARI)a 5 (23.8) 6 (27.3) 0.795
Antecedent diarrhea 15 (71.4) 6 (27.3) 0.004a
Mechanical ventilation 20 (95.2) 5 (22.7) <0.0001a
Plasmapheresis 20 (95.2) 9 (40.9) <0.0001a
a Significant.
ARI: acute respiratory infection.
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antiganglioside antibody positive. On the other hand, most
AIDP patients were seronegative. The strong correlation
between antiganglioside antibodies and the subtype of GBS
has been conﬁrmed in previous studies [11, 14, 15]. Similar
to our study, previous studies found a correlation between
GD1b antibody and AMAN subtypes [16–20]. In another
studies, it was anti-GD1a or anti-GM1 [21–23].
Clinical presentation in antiganglioside positive patients
was more frequently associated with severe motor weak-
ness, which necessitated mechanical ventilation and was
also associated with antecedent diarrhea than the serone-
gative patients. Our ﬁndings conﬁrmed that antiganglioside
antibodies determine the clinical severity and the pathop-
hysiology of GBS patients which was in accord with
previous studies [6, 10, 23–25]. Antiganglioside positive
AIDP patients shared also many features with those with
AMAN subtypes indicating that these antibodies play
a signiﬁcant role in determining the clinical features of
GBS subtypes, this fact was conﬁrmed with previous
studies [11, 17].Table V – Clinical features of patients with GBS according to el
AIDP (N = 20) 
Positive (N = 5) Negative (N = 15) 
Age (mean  SD) 6.875  2.75 7.857  2.14 
Sex (M/F) 3/2 10/5 
Antecedent infections (%):
Acute respiratory infections 20 26 
Diarrhea 40 6 
Clinical features (%):
Bulbar palsy 40 33 
Motor paralysis 100 80 
Sensory impairment 20 86 
Therapy (%):
Mechanical ventilation 100 20 
Plasmapheresis 100 40 
a Significant.Out of 21 antiganglioside positive patients, 95% failed to
respond to IVIG and responded well to plasmapheresis
compared to only 41% of antiganglioside negative patients
(P < 0.001). The exact mechanism is still debated and an
ongoing challenge. Although many studies have shown
equivalent efﬁcacy of both plasmapheresis and IVIG in GBS
patients, they did not evaluate both treatment options in
antiganglioside positive patients [2, 26–28]. In accord to
our study, Dada and Kaplan 2004 [29] concluded that
plasmapheresis may be a superior treatment option as
compared to IVIG in patients with GBS and EMG ﬁndings
of axonal involvement. In addition, a recent Cochrane
meta-analysis of 6 randomized studies showed that plas-
mapheresis is the recommended option in protracted
severe GBS patients who fail to respond to both IVIG and
corticosteroids [30].
One of the current study limitations, is that all patients
were recruited in the pediatric intensive care unit (PICU),
so mild cases could be missed. Another limitation is the
time of PICU admission; patients in the present study
were admitted within the ﬁrst 2 weeks of neurologicalectrodiagnosis and anti-ganglioside antibodies
P value AMAN (N = 23) P value
Positive (N = 15) Negative (N = 8)
0.412 7.800  2.68 266  2.71 0.707
0.786 10/5 5/3 0.795
0.278 25 28.6 0.680
0.070 81.2 71.4 0.782
0.787 25 28.5 0.931
0.043a 100 71.4 0.530
0.024a 6.3 43 0.063
0.001a 93.7 28.5 0.001a
0.020a 93.7 42.8 0.004a
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because the clinical ﬁndings might differ from day to
day.
Conclusion
Antiganglioside antibodies patients constitute a major
subtype of GBS among Egyptian children. They may be
more reliable than electrodiagnosis in determining the
clinical severity and predicting the ongoing response to
therapy. Plasmapheresis is superior to IVIG as a treatment
option for antiganglioside positive patients. Therefore,
determination of antiganglioside antibodies should be an
integral early test for evaluation of patients with GBS
especially in the ﬁrst two weeks from the onset of
neuropathy, Where electrodiagnosis is inconclusive. We
suggest that the results of the study warrant additional
studies which would include a larger number of patients
that include the mild cases and be conducted in other
countries.
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